Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis
- 1 January 1997
- journal article
- Published by Elsevier in Kidney International
- Vol. 51 (1) , 187-194
- https://doi.org/10.1038/ki.1997.23
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Amyloid β2-microglobulin is modified with Nε-(carboxymethyl)lysine in dialysis-related amyloidosisKidney International, 1996
- Advanced oxidation protein products as a novel marker of oxidative stress in uremiaKidney International, 1996
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995
- Elevated Serum Levels of 3-Deoxyglucosone, a Potent Protein-Cross-Linking Intermediate of the Maillard Reaction, in Uremic PatientsNephron, 1995
- Presence of 3-Deoxyglucosone, a Potent Protein Crosslinking Intermediate of Maillard Reaction, in Diabetic SerumBiochemical and Biophysical Research Communications, 1993
- beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.Journal of Clinical Investigation, 1993
- Hemoglobin-AGE: A Circulating Marker of Advanced GlycosylationScience, 1992
- β2-microglobulin: A new form of amyloid protein associated with chronic hemodialysisKidney International, 1986
- Serum Levels of β2-Microglobulin as a New Form of Amyloid Protein in Patients Undergoing Long-Term HemodialysisNew England Journal of Medicine, 1986
- A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulinBiochemical and Biophysical Research Communications, 1985